Aether Industries Ltd

- The transcript from the Q2 FY24 earnings call does not mention any current or planned fundraising through debt or equity. - No discussions or questions on new debt or equity issuance were raised during the call. - The company is focusing on aggressive CAPEX and expansion plans funded through internal accruals or existing resources. - There are no indications of immediate plans for external fundraising within the provided transcript. - Shareholding compliance deadline mentioned is by May 2025, but no related fundraising mentioned.

- CAPEX plans advancing aggressively on Greenfield manufacturing Sites 3++, Site-IV, and Site-V. - Site-III+ and 3++: Machinery and equipment procurement underway; regulatory approvals applied. - Planned production of 3-5 products in agrochemicals and pharmaceuticals upon commercialization of Site-III+ and 3++. - Site-IV: Construction ongoing; expected operational by end of current financial year; initially dedicated to contract/exclusive manufacturing, especially oilfield services agreement with US company. - Secondary construction at Site-IV planned for commercialization agreement with Saudi Aramco Technologies on Converge polyols platform. - Site-V: Regulatory approvals applied, fencing and initial civil work begun; envisioned as a large industrial estate with 16+ production blocks, focusing on sustainability and advanced technology. - Additional R&D infrastructure expansion underway with a new R&D center expected in 1-2 years. - Ongoing significant investments in R&D and pilot plants to support CRAMS business and new project pipelines.

- Management expects growth driven primarily by volume increases, despite a 25% year-on-year reduction in realizations due to pricing pressure and Chinese dumping across both pharma and agro segments. - Export contribution is expected to rise, aiming to return to a balanced 50:50 domestic-export revenue mix from the current 66% domestic sales. - New product launches, especially in agrochemicals, are on track with no anticipated delays, and these are expected to contribute to topline growth progressively. - Anticipated full-fledged implementation of the oil field services segment in the next fiscal year, with additional products expected from existing clients and potential new customers. - Recovery signs in agrochemical sector orders, with inventory destocking tapering off and new orders expected in the next two quarters. - Ramp-up from strategic partnerships (e.g., Otsuka) is expected to gradually increase volumes. - Overall, management is confident of improving margins alongside volume growth to sustain future revenue growth.

- Management targets gross margins to improve from current 50-53% range to around 55-56% over the next 2-3 years, indicating margin expansion. - EBITDA grew 18% YoY in H1 FY24 and PAT grew 18%, showing solid profitability growth. - Expect full-fledged implementation and revenue ramp-up from the new oilfield services segment starting FY25. - New product launches in agrochemical and pharmaceutical segments anticipated to contribute significantly in next 3-4 quarters. - Export contribution expected to increase from current 34% to around 50%, broadening revenue base. - Reduction in raw material prices and stable average selling prices support margin expansion. - Volume-driven growth expected to sustain despite price pressures, with product mix improvements. - Inventory and receivables management improving, supporting operational efficiency and profitability. - Overall, management is optimistic on earnings growth driven by volume increase, margin expansion, new product additions, and diversification into new geographies and sectors.

- The company has good visibility on order books for contractual exclusive manufacturing with multiyear contracts and minimum quantity commitments, renegotiated yearly based on raw material prices. - Large-scale manufacturing has good previous year visibility but currently cautious on new large orders due to volatile pricing and raw material instability. - Upcoming orders include approx. Rs. 300 crores (~1600 metric tons) from initial products in MENA region with no impact from current geopolitical tensions. - Agrochemical segment shows revival in orders with demand and deliveries expected in Q3 and Q4 of FY24 after Q2 production buildup. - New contracts in oilfield services are in commissioning and trial order phase with expected full-fledged implementation next fiscal year, including additional products under discussions. - New product launches in pharma and agrochemicals have started contributing to topline; gradual volume increases expected. - No expected delays in new or existing product launches; some partnerships and programs to be announced shortly.